University of Iowa Hospitals and Clinics
Cupid 2b: Enzyme Replacement Therapy for Advanced Heart Failure
A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure. The purpose of this trial is to assess whether MYDICAR can reduce the frequency and/or delay heart failure related hospitalizations in persons with advanced heart failure when added to their maximal and optimized therapy.
Please refer to www.clinicaltrials.gov identifier NCT01643330
for more information.
A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure (CUPID-2b)
Cardiomyopathy Treatment Program
Cynthia Larew, RN BSN
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.